Using a Microdose to Maintain Weight Loss: What the Evidence Says

Once the weight is off, a new question takes over: do you really need to keep taking a full GLP-1 dose forever? The appealing middle path is a "maintenance microdose" — drop to a small fraction of the dose that got you there, spend less, feel fewer side effects, and coast. This page is an honest look at whether that works. The evidence is genuinely more supportive here than for microdosing-to-lose-weight — but it stops short of validating a true microdose, and the gap between "keep taking some" and "take a microdose" is where most of the risk lives.

The short version: the trials are clear that continuing a GLP-1 drug protects your loss while stopping leads to substantial regain. What no trial has tested is whether an intentional microdose — far below the studied maintenance dose — is enough to hold the line. "Stay on it" is evidence-based; "drop to a microdose to stay on it" is an extrapolation.

The maintenance problem, in one trial

The single most important study for this question is STEP 4. People first lost weight on semaglutide, then were randomized either to continue 2.4 mg or switch to placebo. Those who continued kept losing or held steady; those who stopped regained weight steadily over the following months ¹. The benefit follows the drug. Take it away and the body's weight-regain machinery — restored appetite, lowered energy expenditure — reasserts itself.

The STEP 1 trial extension drives the point home. After semaglutide was withdrawn, participants regained about two-thirds of their lost weight within a year, and much of the cardiometabolic improvement reversed alongside it ². This is the honest backdrop to any maintenance plan: GLP-1 weight loss is not a one-time cure you bank and walk away from. It depends on ongoing exposure.

Why "maintenance dose" is real — but "microdose" is a leap

Here's the nuance the trend gets half-right. It is genuinely plausible that maintaining weight takes less drug than losing it: keeping the appetite-suppressing effect steady may not require the same exposure that drove active loss. Clinically, that's why lower maintenance doses exist at all. But notice the scale. The doses studied for maintenance — like the 2.4 mg continued arm in STEP 4 ¹ — are full therapeutic doses, not microdoses. There is no trial that took people down to a true microdose (a small fraction of the maintenance dose) and showed weight held.

So the maintenance logic supports "you may be able to step down somewhat," and it's reasonable for a clinician to find your lowest effective dose. What it does not support is the online pitch that a token microdose will hold a 15% loss in place. That specific claim has no trial behind it, and the dose-response data — where lower doses reliably did less ³ — argue you can step down too far. We lay out that gradient in GLP-1 dose-response: why lower doses do less.

The closest thing to maintenance evidence: the Danish trial

The most relevant real-world maintenance experiment is a Danish randomized trial. After an initial low-calorie weight loss, participants were assigned to exercise, a GLP-1 receptor agonist (liraglutide), both, or placebo — and then followed for a year after treatment stopped. The combination of exercise plus the GLP-1 drug was best at maintaining the loss during treatment; but once treatment ended, weight crept back, and the group that had relied on the drug alone fared worse off-treatment than the group that had built an exercise habit ⁴.

Two honest lessons come out of that trial. First, a GLP-1 drug genuinely helps hold weight loss while you're taking it — supporting the "stay on something" idea. Second, the drug is not a substitute for the behavioral foundation: when it's removed, the people with an exercise habit kept more of their loss. A maintenance strategy that is only a microdose and no lifestyle change is leaning on the weakest version of both.

What a sensible step-down looks like — and its limits

If you and a clinician decide to reduce your dose for maintenance, the honest framing is "find the lowest dose that holds your weight," not "go as low as possible to save money." A reasonable approach steps down gradually and watches what happens, because regain is the signal that you've gone below your effective dose.

But three caveats keep this from being a free lunch:

• •It's still indefinite. A maintenance dose — even a smaller one — is ongoing treatment. The STEP data show the loss is conditional on continued exposure ¹². Stepping down is not a path to stopping.
• •Too low and you lose the effect. Because effect scales with dose ³, a dose driven by budget rather than biology risks landing below the threshold that maintains your weight — at which point you're paying for regain.
• •The non-weight benefits don't downscale on evidence. Whatever cardiovascular protection a full dose provides (semaglutide 2.4 mg cut major cardiovascular events ~20% in SELECT) was shown at the full dose ⁵; there's no evidence a maintenance microdose preserves it. We unpack that in low-dose vs full-dose GLP-1: what actually changes.

The compounding caveat

Most "maintenance microdosing" in practice means self-adjusting compounded GLP-1 — drawing small amounts from a vial or counting pen clicks. That adds a grey-market risk layer on top of the dosing uncertainty. A pharmacovigilance analysis of compounded GLP-1 agonists found markedly elevated reporting odds for preparation errors, contamination, and compounding problems, plus more reports of abdominal pain and hospitalization ⁶. The microdosing-specific clinical literature is explicitly cautionary about dosing errors and pen manipulation in exactly this DIY-maintenance context ⁷. A maintenance plan built on self-measured compounded product is carrying that risk indefinitely. See is compounded / microdosed GLP-1 safe.

The honest bottom line

The evidence genuinely supports staying on a GLP-1 drug to maintain weight loss — stopping leads to substantial regain, and that's well documented (STEP 4, the STEP 1 extension, the Danish maintenance trial). It is also plausible that maintenance takes a somewhat lower dose than active loss, which is why finding your lowest effective dose with a clinician is reasonable. What the evidence does not support is the specific claim that a true microdose — a small fraction of the studied maintenance dose — will hold your weight. That's untested, runs against the dose-response data, and is usually attempted with compounded product carrying its own risks. Maintenance via dose reduction: defensible, individualized, clinician-guided. Maintenance via microdose-and-coast: an unproven extrapolation.

For the wider picture, start with the pillar, microdosing GLP-1 — what the evidence actually shows, and see low-dose vs full-dose GLP-1 and the tirzepatide-specific take in microdosing tirzepatide. To compare maintenance-friendly providers and protocols, use the GLP-1 microdose rankings hub.